Pulmonx Q1 2024 GAAP EPS $(0.36) Beats $(0.46) Estimate, Sales $18.854M Beat $17.893M Estimate
Portfolio Pulse from Benzinga Newsdesk
Pulmonx (NASDAQ:LUNG) reported Q1 2024 earnings with a smaller loss per share of $(0.36) compared to the expected $(0.46), and sales of $18.854M, surpassing the $17.893M estimate. This represents a 14.29% improvement in losses and a 29.71% increase in sales year-over-year.
May 01, 2024 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pulmonx reported a smaller Q1 2024 loss of $(0.36) per share, beating estimates, and sales of $18.854M, exceeding expectations. Year-over-year, losses improved by 14.29% and sales increased by 29.71%.
Pulmonx's Q1 2024 earnings report showing better-than-expected losses and sales growth is likely to positively impact investor sentiment and the stock price in the short term. The significant improvement in both earnings and sales compared to the previous year indicates strong operational performance and could lead to increased investor confidence.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100